Improved cost efficacy and safety for CNS immunotherapy

Purpose and goal

The aim of the project was to produce and study bispecific, brain-penetrating antibodies for the treatment of neurodegenerative diseases and to develop the technology towards clinical use. Methods of production have been developed and efficacy studies have been performed.

Expected results and effects

Bispecific antibodies have been developed against proteins involved in Alzheimer´s and Parkinson´s diseases. These antibodies showed a markedly increased uptake in the brains of transgenic mice. Furthermore, efficacy could be demonstrated with a ten times lower dose than with traditional unmodified antibodies. As a result, significantly lower doses should be possible to give to patients with maintained treatment efficacy. Also manufacturing costs for a drug should be significantly reduced.

Planned approach and implementation

The project progressed according to the plan outlined in the application. The establishment of a method for producing antibodies was performed and antibodies were evaluated in two different diseases with associated animal models. Studies were thereafter performed with focus on clinical use. Parallel to this, evaluation of biomarkers, was performed as a standalone project.